A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant
advanced solid tumors.

Inclusion Criteria:

- Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose
escalation) or RAS mutations (dose optimization/expansion) identified through
deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).

- Treatment naive or have received prior standard therapy appropriate for tumor type
and stage

- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Adequate organ function

Exclusion Criteria:

- Primary central nervous system (CNS) tumors

- Active, untreated brain metastases

- Known or suspected impairment of gastrointestinal function that may prohibit ability
to swallow or absorb an oral medication

- History of any other unstable or clinically significant concurrent medical condition
that would, in the opinion of the investigator, jeopardize the safety of a
participant, impact their expected survival through the end of the study
participation, and/or impact their ability to comply with the protocol
prior/concomitant therapy

Other inclusion/exclusion criteria may apply.